Pharmaceutical Distribution Agreement (Pakistan)
PHARMACEUTICAL DISTRIBUTION AGREEMENT
Under the Drugs Act 1976 | DRAP Act 2012 | Contract Act 1872
This Pharmaceutical Distribution Agreement is entered into at [City] on [Agreement Date] between:
PRINCIPAL (Manufacturer / Importer):
[Principal Name], registered address: [Principal Address], DRAP Licence No.: [Principal DRAP Licence], NTN: [Principal NTN], represented by [Principal Representative] (hereinafter referred to as the "Principal");
AND
DISTRIBUTOR:
[Distributor Name], registered address: [Distributor Address], Wholesale Drug Licence No.: [Distributor Wholesale Licence] (expiry: [Distributor Licence Expiry]), NTN: [Distributor NTN], represented by [Distributor Representative] (hereinafter referred to as the "Distributor").
1. APPOINTMENT AND PRODUCTS
1.1 The Principal hereby appoints the Distributor as [Exclusivity] distributor of the pharmaceutical products listed below within the Territory, and the Distributor accepts this appointment on the terms and conditions herein.
1.2 Products (each registered with DRAP under Section 7 of the Drugs Act 1976): [Products Schedule]
1.3 Territory: [Territory].
1.4 The Distributor shall distribute only products registered with DRAP and shall not distribute any unregistered, expired, or counterfeit product. Doing so constitutes a criminal offence under the Drugs Act 1976.
2. COMMERCIAL TERMS
2.1 Transfer Price: [Transfer Price].
2.2 Distributor Margin: [Distributor Margin] off the DRAP-approved Maximum Retail Price (MRP) for each product.
2.3 The Distributor shall not sell any product above the DRAP-approved MRP printed on the pack. Selling above MRP is an offence under Section 27 of the Drugs Act 1976.
2.4 Annual Minimum Purchase Obligation: [Minimum Purchase].
2.5 Payment Terms: [Payment Terms] from the date of each invoice.
2.6 The Distributor shall report actual sales data and inventory levels to the Principal on a monthly basis to support DRAP's market surveillance and pharmacovigilance requirements.
3. DRAP COMPLIANCE AND STORAGE
3.1 The Distributor shall maintain all products in conditions compliant with DRAP's Good Distribution Practice (GDP) guidelines. Required storage temperature: [Storage Requirements].
3.2 The Distributor shall maintain valid wholesale drug licences and all other regulatory approvals throughout the agreement term and notify the Principal immediately if any licence is suspended, revoked, or not renewed.
3.3 Pharmacovigilance: The Distributor shall collect and forward adverse drug reaction (ADR) reports and product quality complaints to the Principal within 24 hours of receipt for serious adverse reactions and within 15 calendar days for non-serious reactions, in compliance with the DRAP Act 2012 and DRAP's National Pharmacovigilance Policy.
3.4 Anti-Counterfeiting: The Distributor shall implement serialisation scanning infrastructure in compliance with DRAP's Track and Trace System (TTS), report any suspected counterfeit product to the Principal and to DRAP under Section 26 of the Drugs Act 1976, and cooperate fully in product recalls.
3.5 The Principal shall have the right to audit the Distributor's warehouses and records on reasonable notice to verify GDP compliance and licence status.
4. TERM AND TERMINATION
4.1 This Agreement shall remain in force for [Agreement Term] from the date of execution, unless terminated earlier in accordance with this clause.
4.2 Either party may terminate this Agreement without cause on [Notice Period] to the other party.
4.3 The Principal may terminate this Agreement immediately without notice if the Distributor: (a) loses its wholesale drug licence; (b) breaches DRAP compliance obligations; (c) sells products above the DRAP-approved MRP; (d) distributes products outside the Territory; or (e) becomes insolvent.
4.4 Upon termination, the Distributor shall immediately cease promoting and selling the Principal's products, return all promotional materials, and either return or sell through unsold stock within the agreed wind-down period.
5. GENERAL TERMS
5.1 This Agreement is governed by the Drugs Act 1976, the DRAP Act 2012, and the Contract Act 1872 of the Islamic Republic of Pakistan.
5.2 Any dispute shall be resolved by arbitration under the Arbitration Act 1940 in [City], failing which by the courts of [City].
5.3 The Distributor is an independent contractor and not an agent, employee, or partner of the Principal.
5.4 This Agreement does not grant the Distributor any right to use the Principal's trade marks registered under the Trade Marks Ordinance 2001 except in connection with authorised distribution of the Products.
Principal (Manufacturer / Importer) — Authorised Signatory
________________
Signature
Distributor — Authorised Signatory
________________
Signature
What Is a Pharmaceutical Distribution Agreement (Pakistan)?
A Pharmaceutical Distribution Agreement in Pakistan is a formal commercial contract between a pharmaceutical manufacturer or importer (the principal) and a licensed distributor, by which the distributor is appointed to distribute, market, and sell registered pharmaceutical products within a defined territory in Pakistan. The Pharmaceutical Distribution Agreement (Pakistan) is governed by the Drugs Act 1976 (Act No. XXXI of 1976), the Drug Regulatory Authority of Pakistan Act 2012 (DRAP Act 2012), and the Drug Regulatory Authority of Pakistan's (DRAP's) thorough licensing and registration requirements for pharmaceutical supply chain participants.
The Drugs Act 1976 is the foundational statute governing the manufacture, import, export, storage, distribution, and sale of drugs in Pakistan. Section 7 of the Drugs Act 1976 prohibits the manufacture, import, export, or sale of any drug that is not registered with the DRAP under Section 7A. Section 14 of the Drugs Act 1976 requires that no person shall sell or stock any drug unless they hold a valid licence issued by the DRAP or the provincial health department. A pharmaceutical distributor must hold a valid wholesale drug licence under Section 14 of the Drugs Act 1976, issued by the relevant provincial health authority or the DRAP for federally licensed entities.
The Drug Regulatory Authority of Pakistan Act 2012 established DRAP as an autonomous federal regulatory body responsible for regulating therapeutic goods, biological products, medical devices, and cosmetics in Pakistan. DRAP replaced the Federal Ministry of Health's drug control functions and operates under the direct authority of the Federal Cabinet. DRAP's functions include product registration, licensing of manufacturers, importers, and distributors, post-market surveillance, and enforcement action against substandard, spurious, or unregistered products under the Drugs Act 1976.
Pakistan's pharmaceutical sector is one of the largest in South Asia — with approximately 750 licensed pharmaceutical manufacturers, 85,000 pharmacies, and an extensive wholesale distribution network regulated by DRAP and provincial health departments. The principal pharmaceutical legislation includes the Drugs Act 1976, the DRAP Act 2012, the Drug (Licensing, Registering and Advertising) Rules 1976, the Import Policy Order issued annually by the Ministry of Commerce, and the Pharmacy Act 1967 (which regulates pharmacists and retail sale of drugs). The National Pharmaceutical Policy 2007 provides the framework for confirming access to essential medicines across Pakistan.
A Pharmaceutical Distribution Agreement must be carefully drafted to comply with DRAP's requirements for distributor appointments — DRAP requires manufacturers to disclose their distribution arrangements and maintains a list of authorised distributors for each registered product. The agreement must also address the cold chain requirements for temperature-sensitive pharmaceutical products, the serialisation and track-and-trace requirements introduced by DRAP to combat counterfeit medicines, and the pharmacovigilance obligations of both manufacturer and distributor under the DRAP Act 2012 and DRAP regulations.
The legal framework governing the Pharmaceutical Distribution Agreement (Pakistan) in Pakistan draws on several key statutes and regulatory bodies. Under the Companies Act 2017, the Securities and Exchange Commission of Pakistan (SECP) maintains the register of Pakistani companies. Section 16 of the Companies Act 2017 governs company incorporation. The Contract Act 1872 governs general contractual obligations. The Federal Board of Revenue (FBR) administers corporate tax under the Income Tax Ordinance 2001. The High Courts (Lahore, Sindh, Peshawar, Balochistan, Islamabad) have original and appellate jurisdiction. Parties executing a Pharmaceutical Distribution Agreement (Pakistan) in Pakistan should confirm the document reflects current law, including any amendments enacted since the original drafting date. The Drugs Act 1976 sets the foundational requirements.
When Do You Need a Pharmaceutical Distribution Agreement (Pakistan)?
A Pharmaceutical Distribution Agreement in Pakistan is required whenever a pharmaceutical manufacturer, importer, or marketing authorisation holder appoints a licensed distributor to distribute their registered products through Pakistan's pharmaceutical supply chain.
A Pharmaceutical Distribution Agreement is needed when a foreign pharmaceutical company that has registered its products with DRAP wishes to appoint a Pakistani company as its sole or exclusive importer and distributor. The foreign company (the marketing authorisation holder) must hold a valid product registration certificate from DRAP and appoint an importer registered with DRAP under the Drug (Licensing, Registering and Advertising) Rules 1976. The Distribution Agreement specifies the products covered, the import volume obligations, territory, pricing, and the reporting obligations required by DRAP.
A Pharmaceutical Distribution Agreement is required when a Pakistani pharmaceutical manufacturer distributes products through a network of regional wholesale distributors across Punjab, Sindh, KPK, Balochistan, Azad Kashmir, and Gilgit-Baltistan. Each regional distributor must hold a valid wholesale drug licence and the manufacturer must document the distribution arrangement as part of DRAP's Good Distribution Practice (GDP) compliance framework.
A Pharmaceutical Distribution Agreement is needed when a distributor who previously held a distribution arrangement with a pharmaceutical company wishes to formalise or renew the agreement on new terms — for example, after a price revision under the Drug Regulatory Authority of Pakistan's Drug Pricing Policy, or following a change in the product registration holder due to a merger or acquisition in the pharmaceutical industry.
A Pharmaceutical Distribution Agreement is required when a hospital or institutional buyer — such as a government hospital under a Provincial Health Department, a military hospital under the Army Medical Corps, or a large private hospital group — establishes a direct supply arrangement with a manufacturer or importer and the arrangement needs to be documented to comply with DRAP's supply chain transparency requirements and public procurement rules under the PPRA Ordinance 2002.
A Pharmaceutical Distribution Agreement is needed when a pharmaceutical distributor is appointed as the sole distributor for a controlled substance (narcotic or psychotropic drug) regulated under the Control of Narcotic Substances Act 1997 (CNSA 1997) administered jointly by the Anti-Narcotics Force (ANF) and the Ministry of Narcotics Control — where strict quantity controls, record-keeping, and reporting obligations apply in addition to standard DRAP licensing requirements.
What to Include in Your Pharmaceutical Distribution Agreement (Pakistan)
A valid Pharmaceutical Distribution Agreement in Pakistan under the Drugs Act 1976, the DRAP Act 2012, and the Contract Act 1872 must contain the following essential elements to be commercially effective and DRAP-compliant.
Parties and Licences: Full legal name, registered address, DRAP licence number, NTN (National Tax Number) from the Federal Board of Revenue (FBR), and SECP company registration number of both the principal (manufacturer or marketing authorisation holder) and the distributor. The distributor's wholesale drug licence number and expiry date must be stated. The agreement must oblige the distributor to maintain valid licences throughout the term and immediately notify the principal if any licence is suspended or revoked.
Product Schedule: A detailed schedule of the pharmaceutical products covered by the agreement — including the DRAP product registration number for each product (mandatory for all products distributed in Pakistan under Section 7 of the Drugs Act 1976), the trade name, generic name (INN — International Non-proprietary Name), dosage form, strength, pack size, and shelf life. Products must not be added or removed without written amendment.
Territory and Exclusivity: The geographic territory within which the distributor is authorised to distribute — whether all of Pakistan, specific provinces (Punjab, Sindh, KPK, Balochistan), or specific cities. Whether the appointment is exclusive (preventing the principal from appointing other distributors in the same territory or selling directly to customers in the territory) or non-exclusive. Exclusivity provisions must not violate the Competition Act 2010 administered by the Competition Commission of Pakistan (CCP).
Pricing and Drug Pricing Policy Compliance: The agreed transfer price from principal to distributor (ex-factory or CIF price for imports), and the distributor's obligations regarding the Maximum Retail Price (MRP) printed on each pack and set by DRAP under the Drug Pricing Policy. Distributors must not sell products above the MRP prescribed by DRAP — violations attract enforcement action under Section 27 of the Drugs Act 1976. The agreement must address how price revisions approved by DRAP are implemented in the supply chain.
Minimum Purchase Obligations and Forecasting: Annual or quarterly minimum purchase quantities or value commitments by the distributor, promotional investment obligations, and the reporting of sales data and inventory levels to the principal as required by DRAP's market surveillance and pharmacovigilance systems.
Storage and Cold Chain: The distributor's obligation to store pharmaceutical products in conditions compliant with DRAP's Good Distribution Practice (GDP) guidelines — temperature and humidity requirements, cold chain infrastructure for vaccines and biologics, and pest control. Right of the principal to audit the distributor's warehouses.
Pharmacovigilance Obligations: The distributor's obligation to report adverse drug reactions, product quality complaints, and suspected counterfeit products to the principal and to DRAP under DRAP's pharmacovigilance regulations, in compliance with the DRAP Act 2012 and DRAP's National Pharmacovigilance Policy.
Forms-legal.com provides this Pharmaceutical Distribution Agreement (Pakistan) template as a practical starting point compliant with the Drugs Act 1976, the DRAP Act 2012, the Drug (Licensing, Registering and Advertising) Rules 1976, and the Contract Act 1872. Pharmaceutical companies should engage a legal advisor with specialist knowledge of DRAP regulations to customise the agreement to their specific product portfolio and distribution model.
Additional compliance elements for a Pharmaceutical Distribution Agreement (Pakistan) used in Pakistan include: Under the Companies Act 2017, the Securities and Exchange Commission of Pakistan (SECP) maintains the register of Pakistani companies. Section 16 of the Companies Act 2017 governs company incorporation. The Contract Act 1872 governs general contractual obligations. The Federal Board of Revenue (FBR) administers corporate tax under the Income Tax Ordinance 2001. The High Courts (Lahore, Sindh, Peshawar, Balochistan, Islamabad) have original and appellate jurisdiction. Forms-legal.com provides this template as a starting point for Pakistan-compliant documentation.
Cite this page
Reference this free template in an article, syllabus, or research note:
Forms Legal. (2026). Pharmaceutical Distribution Agreement (Pakistan) (Pakistan) [Legal document template]. Forms Legal. https://forms-legal.com/pakistan/business/contracts/pharmaceutical-distribution-agreement-pakistan
"Pharmaceutical Distribution Agreement (Pakistan) (Pakistan)." Forms Legal, 2026, https://forms-legal.com/pakistan/business/contracts/pharmaceutical-distribution-agreement-pakistan.
@misc{formslegal-pharmaceutical-distribution-agreement-pakistan,
author = {{Forms Legal}},
title = {Pharmaceutical Distribution Agreement (Pakistan) (Pakistan)},
year = {2026},
howpublished = {\url{https://forms-legal.com/pakistan/business/contracts/pharmaceutical-distribution-agreement-pakistan}},
note = {Free legal document template}
}Frequently Asked Questions
A pharmaceutical distributor in Pakistan must hold several licences to legally distribute pharmaceutical products. The primary requirement is a wholesale drug licence issued under Section 14 of the Drugs Act 1976 by the relevant provincial health authority — the Punjab Health Department, Sindh Health Department, KPK Health Department, or Balochistan Health Department — for distribution within the respective province. Distributors operating across multiple provinces need separate licences from each provincial health authority, or a federal DRAP licence for nationally authorised distributors. The distributor's premises must comply with DRAP's Good Distribution Practice (GDP) guidelines — including adequate storage space, temperature controls, and a qualified pharmacist or pharmaceutical technician supervising operations under the Pharmacy Act 1967. The distributor must also be registered with the Federal Board of Revenue (FBR) for sales tax purposes under the Sales Tax Act 1990 and must maintain NTN registration. For importing pharmaceutical products, a separate import licence from DRAP and an Import Authorisation Letter are required under the Drug (Licensing, Registering and Advertising) Rules 1976.
DRAP's Drug Pricing Policy sets the Maximum Retail Price (MRP) for all registered pharmaceutical products in Pakistan. Manufacturers must obtain DRAP approval for the MRP before marketing any product, and the approved MRP is printed on each pack. Distributors and retailers are prohibited from selling products above the DRAP-approved MRP under Section 27 of the Drugs Act 1976 — violations attract seizure, fine, and licence suspension. The Pharmaceutical Distribution Agreement must incorporate the current DRAP-approved MRP for each product and specify the mechanism for implementing DRAP-approved price revisions — for example, how existing stock purchased at the old price is to be handled when DRAP approves an increase or decrease. The agreement must also specify the distributor's margin (the percentage discount off the MRP at which the principal supplies the distributor), which must allow the distributor to profitably sell products at or below the MRP while also accommodating the retailer's margin. DRAP's drug pricing reforms periodically revise the MRP structure, and the agreement should include a force majeure or regulatory change clause addressing price regulation changes.
Under the DRAP Act 2012 and DRAP's National Pharmacovigilance Policy, pharmaceutical distributors in Pakistan are required to collect, report, and forward adverse drug reaction (ADR) reports, product quality complaints, and information about suspected counterfeit or substandard medicines to the marketing authorisation holder (principal) and, in serious cases, directly to DRAP's pharmacovigilance cell. An adverse drug reaction is any noxious and unintended response to a medicinal product at doses normally used in humans for prophylaxis, diagnosis, or therapy. Distributors must maintain a complaint log recording all product quality complaints received from pharmacies, hospitals, and patients, including the product name, batch number, complaint description, and the action taken. The Pharmaceutical Distribution Agreement should clearly allocate pharmacovigilance responsibilities between the principal and the distributor, specify the timeframe for reporting (typically 24 hours for serious unexpected adverse reactions and 15 calendar days for non-serious reactions in line with WHO guidelines referenced in DRAP's pharmacovigilance guidelines), and require the distributor to cooperate in product recalls initiated by the principal or ordered by DRAP under Section 26 of the Drugs Act 1976.
A Pharmaceutical Distribution Agreement in Pakistan can be terminated before the end of its agreed term in several circumstances. Most agreements specify a notice period for termination without cause — typically 30 to 90 days' written notice — during which the parties continue to perform their obligations. Termination for cause (immediate termination without notice) is usually permitted where the distributor loses their wholesale drug licence under the Drugs Act 1976, breaches DRAP compliance obligations, fails to meet minimum purchase obligations, sells products above the DRAP-approved MRP, distributes products outside the agreed territory, or becomes insolvent. The principal must also be able to terminate if DRAP revokes or refuses to renew the product registration for a product covered by the agreement. Upon termination, the distributor must immediately cease promoting and selling the principal's products, return all promotional materials, and either return unsold stock to the principal (for which the principal may pay a restocking fee) or sell through remaining stock within a wind-down period. The termination provisions must not violate the Competition Act 2010 — agreements imposing unreasonably long notice periods or post-termination restrictions may be scrutinised by the Competition Commission of Pakistan.
Counterfeit and substandard medicines are a serious public health concern in Pakistan, and DRAP has introduced serialisation and track-and-trace requirements to combat them. Under DRAP's Track and Trace System (TTS) — initially rolled out for the tobacco sector and being extended to pharmaceuticals — pharmaceutical manufacturers must apply unique serialisation codes to each pack, and distributors must scan these codes upon receipt and dispatch to maintain a digital trail. The Pharmaceutical Distribution Agreement should require the distributor to implement compatible serialisation scanning infrastructure, maintain records of batch numbers and quantities received and dispatched, report any suspected counterfeit products immediately to the principal and to DRAP under Section 26 of the Drugs Act 1976, and cooperate fully in any DRAP investigation or product recall. Distributors who knowingly distribute counterfeit products are liable to prosecution under the Drugs Act 1976 and the Prevention of Electronic Crimes Act 2016 (for digital falsification of serialisation data). The principal's intellectual property — trade marks registered under the Trade Marks Ordinance 2001 — must be protected through the distribution agreement by restricting the distributor to authorised sales channels only.
This template is provided for informational purposes only and does not constitute legal advice. Laws vary by jurisdiction and change over time. Consult a qualified attorney for advice specific to your situation.Full disclaimer
Found an error? Let us knowRelated Documents
You may also find these documents useful:
Distribution Agreement (Pakistan)
A Distribution Agreement for Pakistan — a contract between a supplier or manufacturer and a distributor appointing the distributor to sell and market products in a defined territory, governed by the Contract Act 1872 and applicable trade regulations.
Agency Agreement (Pakistan)
An Agency Agreement for Pakistan — a contract appointing an agent to act on behalf of a principal in business transactions, governed by the Contract Act 1872 (Chapter X: Agency) and the Sale of Goods Act 1930. Defines authority, commission, duties, and termination.
Food Supply Agreement (Pakistan)
A Food Supply Agreement for Pakistan — a commercial contract between a food supplier and a buyer (retailer, restaurant, institution, or distributor) governing the regular supply of food products under the Sale of Goods Act 1930, Punjab Food Authority Act 2011, and Pakistan Standards and Quality Control Authority (PSQCA) regulations.
Import Permit Application (Pakistan)
An Import Permit Application for Pakistan — a formal application to the Ministry of Commerce or relevant licensing authority for permission to import controlled or restricted goods, governed by the Imports and Exports (Control) Act 1950, the Import Policy Order issued annually, and Pakistan Customs Rules under the Customs Act 1969.
Independent Contractor Agreement (Pakistan)
An Independent Contractor Agreement for Pakistan — a legally binding contract defining the terms of engagement between a business and a self-employed individual or firm, governed by the Contract Act 1872, distinguishing contractor status from employment under the West Pakistan Industrial and Commercial Employment (Standing Orders) Ordinance 1968.